在实体器官移植接受者患有EBVDNAemia的移植后风险和PTLD的风险
Evelyn H Orlando1,2, Patrick Gould1, Brian Cuzzo3
1Department of Medicine, Columbia University Irving Medical Center, New York, NY.
Blood neoplasia
|October 23, 2025
概括
移植后rituximab可能会减少移植后淋巴增殖障碍 (PTLD) 固体器官移植 (SOT) 接受者与爱斯坦-巴尔病毒 (EBV) DNAemia. 然而,需要进一步的研究来证实其预防性益处.
科学领域:
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
- 病毒学 病毒学
背景情况:
- 埃普斯坦-巴尔病毒 (EBV) 血是实体器官移植 (SOT) 受体中移植后淋巴增殖性疾病 (PTLD) 的已知危险因素.
- 虽然在骨髓移植后使用预防性利图西马布,但对SOT接受者的数据有限.
研究的目的:
- 调查移植后rituximab与SOT接受者经历EBVDNAemia的PTLD发展之间的关联.
- 在这个患者群体中探索PTLD的潜在风险因素.
主要方法:
- 一个回顾性队列研究1386个SOT接受者与EBVDNAemia从2008-2023.
- 对接受Rituximab患者与未接受Rituximab患者中PTLD发展的分析.
- 多变量分析以确定PTLD的独立预测因子.
主要成果:
- 总体而言,6%的患者患有PTLD,而5年无PTLD存活率为95%.
- 移植后的瑞克西马布暴露与PTLD (HR,0.16;P = .011) 的降低率有关,作为一个独立于时间的变量.
- 较高的EBV病毒载量,高风险的移植类型和高风险的EBV血清状态独立地与增加的PTLD率有关.
结论:
- 移植后的rituximab可能与SOT接受者患有EBVDNAemia的PTLD发病率降低有关.
- 较高的EBV病毒载量和特定的移植特征是PTLD的重要风险因素.
- 需要进行前性随机试验,以确定预防性利图西马布在患有EBV DNAemia的SOT接受者中预防PTLD的疗效.
更多相关视频
相关概念视频
01:29Pulmonary Tuberculosis I
822
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
822
01:22Bone Marrow Sampling and Transplants
876
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
876
01:28Kidney Transplant I: Introduction
339
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
339
01:40Cell-mediated Immune Responses
83.4K
Overview
83.4K